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Classical swine fever (CSF) is an infectious disease responsible for high economic
losses in pigs of all ages. Several programs for the control and eradication of this disease have been
implemented at a global level, being vaccination the principal mechanism. This research had the
purpose of identifying the pathogenicity of an isolated circulating strain in Ecuador, and determining
the efficacy of the vaccine applied for prevention. Animals were challenged with decreasing doses of
the viral strain ECJB 2000 to obtain 10 median infective doses of this strain in pigs (DI50). Afterward,
the efficacy of a vaccine of the lapinized Chinese strain was evaluated against the virus of porcine
cholera adapted to a cell culture line derived from a miniature pig kidney (MPK-LC-HCV), averaging
a trial potency following the standard protocol of the World Organization for Animal Health (OIE).
The vaccine was applied at different dilutions, and 14 days later, a viral challenge was done with DI50.
The unimmunized pigs presented clinical signs from day three post-infection, and the statistical results
did not show significant differences in the body temperature registers and leukocyte count. Spearman-
Kärber’s trial determined that the vaccine contained 239.88 protective doses (DI50); taking into
account that an effective vaccine against classical swine fever virus (CSFV) must have a value of >
100. This study demonstrated that the circulating strain in Ecuador is of elevated pathogenicity and
that the vaccine is effective for the control of the disease.
Classical Swine Fever, efficacy, challenge, immunization, strain ECJB 2000.
La peste porcina clásica (PPC) es una enfermedad infecciosa responsable de altas
pérdidas económicas en cerdos de todas las edades. Varios programas para el control y la erradicación
de esta enfermedad se han implementado a nivel mundial, pero el mecanismo principal es la
vacunación. Esta investigación tuvo como objetivo determinar la patogenicidad de una cepa circulante
aislada en Ecuador y determinar la eficacia de la vacuna aplicada para la prevención. Los animales
fueron desafiados con dosis decrecientes de la cepa viral ECJB 2000 para obtener 10 dosis infectivas
medianas de esta cepa (DI50) en cerdos. Posteriormente, se evaluó la eficacia de una vacuna de la cepa
china lapinizada contra el virus del cólera porcino, adaptado a una línea de cultivo celular derivada de
riñón de cerdo en miniatura (MPK-LC-HCV), promediando una potencia de prueba y siguiendo el
protocolo estándar de la Organización Mundial de Sanidad Animal (OIE). La vacuna se aplicó a
diferentes diluciones y, a los catorce días de aplicada, se realizó un desafío viral con DI50. Los cerdos
no inmunizados presentaron signos clínicos desde el día 3, posterior a la infección. Los resultados no
mostraron diferencias significativas en los registros de temperatura corporal y en el recuento de
leucocitos. El ensayo de Spearman-Kärber determinó que la vacuna contenía 239,88 dosis protectoras
(DI50), si se tiene en cuenta que una vacuna eficaz contra el virus de la peste porcina clásica (CSFV)
debe tener un valor > 100. Este estudio demostró que la cepa circulante en Ecuador tiene una
patogenicidad elevada y la vacuna es eficaz para el control de la enfermedad.
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Classical swine fever (CSF) is an infectious
disease of wild and domestic pigs, causing a high
morbidity and mortality in the infected animals.
Outbreaks of CSF usually cause high mortality
rate in pigs of all ages and decrease domestic and
international trade of pigs and pork products.
Nowadays CSF is considered a transboundary
disease and it is inclused in the OIE list of
notifiable animal disease (1,2,3). CSF has been
eradicated in countries of the European Union
and North America, but it is still present in
countries of Asia, Central and South America
like Ecuador (4), where it is an endemic disease,
currently causing great economic losses to pig
farmers in several Ecuadorian provinces.
In the year 2000, FAO (Food and Agriculture
Organization of the United Nations) established a
continental plan for the control and eradication of
CSF for the Americas and the Caribbean, which
will last until the year 2020 (5). In Ecuador, the
National Program for the Control and Eradication
of Classical Swine Fever has worked since 2011
(6). This program approved the classical swine
fever virus (CSFV) attenuated Chinese strain
based vaccines and it demands the mandatory
vaccination of weaned pigs (45 days old), sows
and boars.
The vaccine efficacy test is regulated by OIE
as quality control of vaccine batches. In the test,
the efficacy is estimated in vaccinated animals
directly, by evaluating their resistance to live
virus challenge and it is expressed by the number
of 50 % protective doses (PD50) (7).
There is a need to unify the efficacy test
protocols for all vaccines produced in Ecuador by
using a unique Ecuadorian isolated virus as
challenge strain. The aim of the present study
was to obtain an Ecuadorian CSF isolate and
assess its pathogenicity for using it as challenge
strain in the efficacy test of CSF attenuated
vaccine batches. Two trials were conducted, the
first one for assessing the virulence of the
Ecuadorian CSF ECJB 2000 isolate. In the
second trial, the suitability of CSF ECJB 2000
isolate as challenge strain was evaluated through
the efficacy test of a CSF attenuated vaccine
batch.
MATERIALS AND METHODS
The isolate ECJB 2000 had been obtained from
collected organs from a pig with clinical signs of
CSF at the year 2000. The 10% organ
homogenate in phosphate buffered saline (PBS)
was prepared and inoculated by intramuscular
way into two healthy and CSF seronegative pigs,
tested by ELISA ID Screen ® Classical Swine
Fever E2 competition. The blood of these
infected animals was taken at the pike of fever
and inoculated again in other two pigs for second
passage. The blood collected from these animals
was fractionated into 10 mL aliquots and stored
at -80 ° C, until be used.
The presence of CSFV RNA in ECJB 2000
isolate was identified by real time RT-PCR. For
the molecular characterization of E2 gen, the
virus was isolated in PK-15 cell cultures growing
in 24 well plates, after two passages. The
presence of CSFV in the supernatant of infected
PK15 cells was detected by two methods: two
steps real time RT-PCR and IPMA using the CSF
monoclonal antibody 21.2 (Prionic). The protocol
for real time CSF detection included RNA
extraction with High Pure RNA Purification Kit
(Roche Ltd) from blood samples and TRIZOL
method for RNA extraction from organ samples.
The reverse transcription was performed using
Transcriptor First Strand cDNA Synthesis kit®
(Roche Ltd). The probes and primers used in the
real time PCR were described by Hoffman et al
(8). The RNA of strain Alfort 187 was used as
positive control and the samples that presented a
value of Ct<40 were considered positive.
The E2 gen of ECJB 2000 second passage was
amplified and the nucleotide sequence was
obtained by Sanger method and named EC-PE2-
JB2p with Genbank accession number
KX586773. The isolate used in this study was
phylogenetically classified into 1.1 genotype of
CSFV (9). Twelve cross breeding Landrace/
Yorkshire swine of 6-8 weeks old, weighting
about 20 kg, serologically negative to CSFV, and
belonging to a non-vaccinated and CSF free herd,
were used in both experiments. The animals were
housed in separate experimental rooms with
Biosecurity Containment Level 3 and they were
handled according to international guidelines for
experimentation with animals. The experiments
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were carried out under the supervision of the
veterinary authorities in Ecuador
(AGROCALIDAD). ELISA test (ID Screen® kit
Classical Swine Fever E2 competition) was used
in order to test the presence of CSF specific
antibodies in the serum samples of each animal.
The first trial consisted in the titration of ECJB
2000 virus in pigs and the evaluation of time
course of viremia and clinical signs to determine
the virulence of the viral isolate. Pigs were
divided into four groups of three pigs each in
order to determine only the median lethal dose 50
(LD50). They were intramuscularly inoculated
with 2 mL of the virus at decreasing dilutions
from group 1 (10-4), group 2 (10-5), group 3 (10-6),
and group 4(10-7).
The efficacy test (second trial) was conducted
as described by OIE (7). The vaccine batch had
been prepared from the Chinese lapinized strain
adapted to grow in the miniature pig kidney cell
culture (MPK-LC-HCV). Briefly, two groups (A
and B) of five pigs were intramuscularly
vaccinated with 2 mL each of 1:40 and 1:160
vaccine dilutions respectively. Group C consisted
of two non-vaccinated animals. Fourteen days
after vaccination, all pigs were challenged with
105 LD50 of ECJB 2000 isolate by intramuscular
injection. All animals were euthanized
approximately 20 days post-challenge (d.p.c.),
with the exception of animals from group C that
were sacrificed in order to avoid suffering.
Rectal temperature and clinical signs were
recorded three days before the viral challenge and
daily during the trial, 10 days for the first trial
and 20 d.p.c. Blood samples with anticoagulant
were taken on day 0, each five d.p.i. and before
euthanasia. These samples were used for
determining leukocyte count and the presence of
CSFV RNA by real time RT-PCR. The
assessment of the clinical signs was carried out
through the semi-quantitative scoring system
developed by Mitteholzer et al. (10). All pigs
showing severe clinical signs were euthanized to
avoid suffering, and their organs (tonsils, spleen,
lymph nodes, kidney, and ileum) were collected
for CSFV RNA detection by real time RT- PCR.
The post mortem macroscopic pathological
lesions were recorded in the euthanized pigs.
RESULTS AND DISCUSSION
In the virulence assessing trial, the inoculated
pigs with decreasing dilutions of ECJB 2000
virus presented severe clinical signs of the
disease, characterized by fever, progressive
deterioration and death before the 15th day after
inoculation. The onset of fever and typical CSF
clinical signs began after 3-5 d.p.i., the rectal
temperature mean increased up to 40°C-41°C.
The groups inoculated with 10-4, 10-5 and 10-6
dilutions were euthanized 6 -8 d.p.i. The fever
and other typical clinical signs of CSF were
evident on the third d.p.i (Figure 1). Two pigs
from group 4 (inoculated with 10-7 dilution)
showed rectal temperatures above 40 °C after 4
d.p.c. The remaining pig (number 12) was
slaughtered at 10th d.p.i., without clinical signs.
The pigs inoculated with 10-5 dilution showed
leukopenia since the fifth d.p.i, while at time of
the euthanasia, leukopenia was identified in
groups inoculated with the dilutions 10-5, 10-6,
and the two symptomatic pigs of the 10-7 group.
At necropsy, the presence of typical hemorrhagic
lesions was observed in the target organs of all
diseased pigs. Those pathological lesions were
not observed in the surviving pig, at the time of
necropsy.
The average score of the clinical signs of the
challenged pigs was calculated (10), obtaining
these results: 20,6 points for group 1; 17,6 points
for group 2; 15,5 points for group 3; and 15
points for group 4, respectively (Table 1).
The titre of ECJB 2000 isolate was 107.25LD
50 /2mL, for calculating the dilution of the viral
preparation used for challenging in the
assessment of the efficacy of the vaccine batch.
The results of the real time RT-PCR
demonstrated the presence of viral CSF RNA in
all the animals challenged with ECJB 2000 of
CSF, with the exception of pig number 12 in
which, CSFV was not detected at 5 d.p.i. (table
2A).
In accordance with Mittelholzer et al. (10) and
other studies conducted with CSFV isolated in
other European countries (11,12), the score of the
Ecuadorian isolate is in the range of high virulent
CSFV strain (peak CS>15). Also ECJB 2000
isolate showed a great capacity for replication
and invasion, producing viremia at just a few
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d.p.i., and persisting until death (1,13). This
could be why it was possible to detect CSF RNA
in the organs from all pigs, including the
surviving pig number 12, that was subclinical
infected. The viral load and the virulence of the
strain determined the course of CSFV infection to
acute or subclinical form as it has been
previously reported (13).
In the second trial after challenge, five pigs
from group A (n=5/5) and four pigs from group
B (n=4/5), all of them vaccinated, did not present
clinical signs and survived. Group C (n=2),
corresponding with the control pigs and pig No
22 (Group B), showed CSF clinical signs and
died 6-8 d.p.c. On day 5 d.p.i., a decrease in the
average leukocyte count was observed in all
groups, but increased in the vaccinated groups. In
group C, leukopenia persisted. Macroscopic
lesions were not observed in the organs of the
pigs that survived the trial. In the control pigs and
No 22 pig, there was a characteristic CSFV
infection in the spleen, mesenteric lymph nodes,
tonsils, and intestines.
After these results, the calculated protective
doses for CSF vaccine batch was 239.88 DP50,
fulfilling the requirements established by OIE
Figure 1. Temperature average on ECJB 2000 inoculated experimental pigs/ Temperatura promedio
en cerdos inoculados experimentalmente con ECJB 2000
Table 1. Clinical sign score in CSF experimental animals./ Puntuación de signos clínicos en
animales experimentalmente infectados con PPC.
No. Parameter Group 1 (10⁻⁴) Group 2 (10⁻⁵) Group 3 (10⁻⁶) Group 4 (10⁻⁷)
 Animal 1 2 3 4 5 6 7 8 9 10 11 12
1 Liveliness 3 3 3 2 2 3 2 2 2 1 1 1
2 Body tension 2 3 3 2 2 3 2 3 2 2 2 2
3 Body shape 2 2 2 2 2 1 2 1 1 1 2 1
4 Breathing (judge before approachingpig) 1 1 1 1 1 1 1 1 1 1 1 1
5 Walking 3 2 3 2 1 3 1 3 1 1 1 1
6 Skin (in particular ears, nose, legsand tail) 0 0 0 2 1 1 1 1 1 2 1 1
7 Eyes/conjunctiva 2 2 2 1 1 2 1 1 1 1 1 1
8 Appetite 3 3 3 2 2 3 2 2 1 2 2 2
9 Defecation 2 2 3 2 1 1 3 1 1 2 3 2
10 Leftovers in feeding trough 2 2 2 2 2 2 2 2 2 2 2 2
 Sumatoria 20 20 22 18 15 20 17 17 13 15 16 14
 Average 20,67 17,67 15,67 15,00
Parameters were classified as normal (score 0), slightly altered (score 1), moderately altered (score 2), or
severe CSF symptoms (score 3). Score from all 10
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(7). In the same way, the research carried out by
Campos et al. (14) and Stojanovicet et al. (15)
have shown the efficacy of the vaccine strains
against CSFV using the OIE standard protocol. In
those studies, they obtained more than 100 DP in
each vaccine as a result. It should be noted that
although this research resulted in the death of
several immunized pigs, the vaccine exceeded the
OIE requirements (7).
Regarding blood samples from vaccinated
animals, viral RNA was not identified on day 14
post vaccination, only after 5 d.p.c. CSF RNA
was detected in the blood samples from all
challenged pigs, including the two control pigs.
One animal from each vaccinated group showed
the presence of CSFV RNA in all blood samples
(Table 2B). In the remaining vaccinated pigs, the
presence of the virus was not detected in blood or
organs.
The Chinese vaccine strain tends to produce a
substantial protection, starting three days after
vaccination, induced by the production of IFN-γ
Table 2A. Detection of Classical Swine Fever virus RNA by real time RT-PCR in blood and organ
samples. / Detección del ARN del virus de la peste porcina clásica mediante RT-PCR en tiempo real en
muestras de sangre y órganos
N° Group (Dilution) Day 0 Day 5 E K S I M.L.N T
1 1 (10-4) - + + + + + + +
2 1 (10-4) - + + + + + + +
3 1 (10-4) - + + + + + + +
4 2 (10-5) - + + + + + + +
5 2 (10-5) - + + + + + + +
6 2 (10-5) - + + + + + + +
7 3 (10-6) - + + + + + + +
8 3 (10-6) - + + + + + + +
9 3 (10-6) - + + + + + + +
10 4 (10-7) - + + + + + + +
11 4 (10-7) - + + + + + + +
12 4 (10-7) - - + + + + + +
A. Pigs inoculated with 10-4 -10 -7 serial dilutions of ECJB 2000 isolate / Cerdos inoculados con diluciones
seriadas 10-4 -10-7 del aislado ECJB 2000.
Table 2B. Detection of Classical Swine Fever virus RNA by real time RT-PCR in blood and organ
samples. / Detección del ARN del virus de la peste porcina clásica mediante RT-PCR en tiempo real en
muestras de sangre y órganos
N° Group (Vaccinedilution) Day 0 Day 5 Day 10 Day 15 Day 20 K S I M.L.N T
13 A (1:40) - + + + + - + + + -
14 A (1:40) - + - - - - - - - -
15 A (1:40) - + - - - + + - - -
16 A (1:40) - + - - - - - + + -
17 A (1:40) - + - - - - - - - -
18 B (1:160) - + - - - - - + + +
19 B (1:160) - + + + + - - - + +
20 B (1:160) - + - - - - - - + +
21 B (1:160) - + - - - - + - + +
22 B (1:160) - + NA NA + + + + + +
23 C (Nonvaccinated) - + NA NA + + + + + +
24 C (Nonvaccinated) - + NA NA + - + + + +
+ (Positive); - (Negative); E (Euthanasia); K (Kidney); S (Spleen); I (Ileum); M.L.N.(Mesenteric Lymph
Nodes); T (Tonsils); NA (Not applicable).
B. Efficacy Test of vaccine batch. Pigs vaccinated with vaccine 1:40 and 1:160 diluted and challenged with
105LD50 of E ECJB 2000 CSF virus / Prueba de eficacia del lote de vacunas. Cerdos vacunados con la vacuna
1:40 y 1: 160 diluidos y desafiados con 105LD50 del virus E ECJB 2000 CSF.
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and neutralizing antibodies directed against the
viral proteins E2 and NS3 (16). On the other
hand, the presence of the CSFV in two
immunized pigs could be because qRT-PCR had
increased sensitivity and it is a specific method
for the detection and quantification of nucleic
acids acids (17,18). The study demonstrated that
the viral strain ECJB 2000 contains
107.25PID50/2mL. Its inoculation in unimmunized
pigs produced clinical signs of CSF compatible
with high pathogenicity viral strains. The vaccine
MPK-LC-HCV was effective against the viral
strain circulating in Ecuador, containing more
than 100 DI50, and its application produced
protection of CSF clinical signs and a transitory
viremia.
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